Akebia Therapeutics, Inc. (AKBA) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Akebia Therapeutics, Inc.'s filing signal turned positive.

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease, with two commercial products: Vafseo (vadadustat) for anemia due to CKD in dialysis patients and Auryxia (ferric citrate) for hyperphosphatemia and iron deficiency anemia in CKD patients. Vafseo, an oral HIF-based treatment, launched in January 2025 and is the only oral HIF-based treatment in the U.S. market. Auryxia, which reached loss of exclusivity in March 2025, faces increasing generic competition. The company is advancing a pipeline of mid-stage rare kidney disease programs, including praliciguat and AKB-097, and early-stage HIF molecules. Akebia aims to establish Vafseo as the standard of care for anemia in dialysis patients and expand its presence in the kidney disease community.

Revenue is primarily driven by sales of its commercial products, Vafseo and Auryxia, in the U.S. The company also generates revenue from license, collaboration, and supply agreements with partners in various territories.